



Recent Advances in Thyroid Hormone Regulation: Toward a New Paradigm for Optimal Diagnosis and Treatment

Rudolf Hoermann^{1*}, John E. M. Midgley², Rolf Larisch¹ and Johannes W. Dietrich^{3,4,5}

¹Department for Nuclear Medicine, Klinikum Lüdenscheid, Lüdenscheid, Germany, ²North Lakes Clinical, Ilkley, United Kingdom, ³Medical Department I, Endocrinology and Diabetology, Bergmannsheil University Hospitals, Ruhr University of Bochum, Bochum, Germany, ⁴Ruhr Center for Rare Diseases (CeSER), Ruhr University of Bochum, Bochum, Germany, ⁵Ruhr Center for Rare Diseases (CeSER), Witten/Herdecke University, Bochum, Germany

OPEN ACCESS

Edited by:

Noriyuki Koibuchi,
Gunma University, Japan

Reviewed by:

Xuguang Zhu,
National Cancer Institute
(NIH), United States
Pieter de Lange,
Università degli Studi della
Campania "Luigi Vanvitelli"
Caserta, Italy

*Correspondence:

Rudolf Hoermann
rudolf.hoermann@gmail.com

Specialty section:

This article was submitted to
Thyroid Endocrinology,
a section of the journal
Frontiers in Endocrinology

Homeostasis and allostasis
of thyroid function:

[https://www.frontiersin.org/
research-topics/4262/homeostasis-
and-allostasis-of-thyroid-function](https://www.frontiersin.org/research-topics/4262/homeostasis-and-allostasis-of-thyroid-function)

Received: 30 October 2017

Accepted: 12 December 2017

Published: 22 December 2017

Citation:

Hoermann R, Midgley JEM, Larisch R
and Dietrich JW (2017) Recent
Advances in Thyroid Hormone
Regulation: Toward a New
Paradigm for Optimal
Diagnosis and Treatment.
Front. Endocrinol. 8:364.
doi: 10.3389/fendo.2017.00364

In thyroid health, the pituitary hormone thyroid-stimulating hormone (TSH) raises glandular thyroid hormone production to a physiological level and enhances formation and conversion of T4 to the biologically more active T3. Overstimulation is limited by negative feedback control. In equilibrium defining the euthyroid state, the relationship between TSH and FT4 expresses clusters of genetically determined, interlocked TSH–FT4 pairs, which invalidates their statistical correlation within the euthyroid range. Appropriate reactions to internal or external challenges are defined by unique solutions and homeostatic equilibria. Permissible variations in an individual are much more closely constrained than over a population. Current diagnostic definitions of subclinical thyroid dysfunction are laboratory based, and do not concur with treatment recommendations. An appropriate TSH level is a homeostatic concept that cannot be reduced to a fixed range consideration. The control mode may shift from feedback to tracking where TSH becomes positively, rather than inversely related with FT4. This is obvious in pituitary disease and severe non-thyroid illness, but extends to other prevalent conditions including aging, obesity, and levothyroxine (LT4) treatment. Treatment targets must both be individualized and respect altered equilibria on LT4. To avoid amalgamation bias, clinically meaningful stratification is required in epidemiological studies. In conclusion, pituitary TSH cannot be readily interpreted as a sensitive mirror image of thyroid function because the negative TSH–FT4 correlation is frequently broken, even inverted, by common conditions. The interrelationships between TSH and thyroid hormones and the interlocking elements of the control system are individual, dynamic, and adaptive. This demands a paradigm shift of its diagnostic use.

Keywords: setpoint, thyroid homeostasis, thyroid-stimulating hormone, levothyroxine treatment

INTRODUCTION

In the healthy body, multiple interlocking biochemical mechanisms interact homeostatically both to achieve biological equilibrium and to respond suitably to any challenges, internal or external, that might occur. However, the way in which different individuals maintain a steady homeostatic state varies considerably, including their appropriate reaction to any changes that

may be demanded of the system. In this regard, the possible biochemical expressions of a healthy framework within which viable variations of response can occur have finite limits (1). Appropriate reactions in individuals are defined by their own unique solutions both to homeostatic equilibrium and to biochemical challenges, which are much more closely constrained than those permissible over the whole population. This has profound implications as to how disequilibria are confronted by individual responses to the challenge or therapeutic interventions administered to obvert it.

The classical definitions of hypothyroidism and hyperthyroidism reflect this concept when referring to inadequate—either reduced or exaggerated—supply and response to thyroid hormones (2). Pathophysiological conditions or diseases may arise at various levels including deficiencies of hormone supply, alterations of control or resistance to cellular responses to the hormones (3–5). Thyroid gland failure represents a more restricted view, termed primary hypothyroidism. Current diagnostic definitions of thyroid disease are primarily laboratory based, and include subclinical dysfunctions that are dissociated from treatment recommendations (6–9). In this review, we revisit underlying principles of thyroid control, aligning or contrasting them with the current use of thyroid-stimulating hormone (TSH) in the diagnosis and treatment of thyroid diseases.

THE CURRENT PARADIGM OF THYROID DIAGNOSIS


Two events have shaped the current paradigm of thyroid function testing (1) the discovery of negative feedback by thyroid hormones on pituitary TSH and (2) methodological advances in sensitively measuring TSH (6, 10, 11). If TSH serum concentrations provided a more sensitive and accurate mirror image of thyroid hormone status than thyroid hormones themselves, this would be an ideal diagnostic tool. This argument emerged in the 1980s, and was readily accepted by clinicians (12, 13). TSH measurement subsequently gained a dominant role in thyroid function testing, facilitating cost effective disease screening, introducing new definitions of subclinical hypothyroidism or hyperthyroidism, and delivering biochemical treatment targets (14–17). A plethora of epidemiological studies then associated TSH concentrations with clinical outcomes (18–21). This resulted in a questionable paradigm elevating an indirect controlling parameter to such prominence and dominance as expressed in current guidelines for diagnosis and treatment of thyroid diseases (14–16). With the holy grail in the hand of scientists, clinically orientated approaches contradicting the TSH paradigm and noting discrepancies between a biochemically euthyroid and clinically hypothyroid status were readily dismissed (22–26). However, concerns have resurfaced in the light of recent basic and clinical studies revealing fundamental issues with the interpretation of TSH measurements and documenting unsatisfactory improvement in the quality of life of patients treated for hypothyroidism according to the current TSH paradigm (1, 27–29).

SHIFTING THE PARADIGM

Is the TSH concentration at all times a reliable mirror image of the thyroid hormone status of the patient?

Firstly, we must note that this question reverses causality of process. While TSH is subject to negative feedback by thyroid hormones predominantly FT₄, thereby reflecting on the thyroid hormone status, its primary physiological role is to elevate the hypothyroid to the euthyroid state (1). Without appropriate stimulation by TSH, the basal hormone output by the thyroid gland remains insufficient, as becomes apparent in pituitary deficiency (secondary hypothyroidism) (4). Conversely, in thyroid health TSH raises the glandular hormone production to its physiological level, and it also enhances the formation of the biologically more active T₃ and its conversion from T₄ (30–32). The integration of the TSH–T₃ shunt into the homeostatic control of the thyroid–pituitary axis is illustrated in **Figure 1A**. Feedback details have been discussed elsewhere (27). Clinical studies and theoretical modeling suggest that the shunt facilitates FT₃ stability against variations in the glandular T₄ output, and its absence may lead to T₃ production instability in athyreotic patients (31, 33). This relational control loop operates still within the euthyroid TSH range (34). It also appears to mediate subtle expressions of central control over peripheral tissues, such as circadian or seasonal variation in FT₃, but not FT₄, the former lagging the TSH rhythm (35). In thyroid autoimmune disease, the feedforward control increases T₄ to T₃ conversion, compensating for latent thyroid failure until the disease has progressed beyond tolerance (34).

Pathophysiological challenges other than thyroid disease may disturb the equilibria between TSH and thyroid hormones, requiring setpoint adjustment of the hypothalamic–pituitary–thyroid axis (**Figures 1A–C**). Weight gain or loss, alterations in body composition, and aging may cause profound changes (**Figure 1C**), frequently switching the control mode from negative feedback to tracking FT₄ rather than opposing it (36, 39, 40). This inversion of the TSH–FT₄ correlation is clinically important to recognize, but it may be missed or misinterpreted as subclinical hypothyroidism when relying on TSH measurement as sole diagnostic test. Several mechanisms provide a physiological interface for shifting the control modes of the hypothalamic–pituitary–thyroid axis (36, 39–46). While detailed examination of the complex subject is beyond the scope of this article and dedicated reviews are available (36, 39, 41, 43, 45, 46), a brief explanation may be helpful. Hypothalamic tancytes strongly express the relatively more T₃- than T₄-affine thyroid hormone transporter MCT8 and deiodinase type 2 and 3, enabling them to sense FT₃ and FT₄ levels (41, 44–46). They also respond to alterations in the energetic and metabolic needs of the body and interact with TRH neurons (41, 42, 44–48). Fat cells release adipokines such as leptin into the circulation which directly or indirectly stimulate pituitary TSH secretion (36, 39, 40, 42, 45). In a vicious cycle, TSH may promote leptin release through TSH receptor activation on adipocytes (49). The controlling system stays informed on fat and energy reserves, and may act on adjusting energy expenditure accordingly. While rising with weight gain TSH decreases again after weight loss



(36, 39, 50, 51). Central and peripheral deiodinases are also sensitive to nutritional factors and body composition, adjusting T4 to T3 conversion to maintain T3 stability under varying conditions (39, 40). As transporters, deiodinases and thyroid hormone receptors subtypes differ in both their expressions and T3 affinities, central responses may readily diverge from peripheral equilibria (52–54). This may explain why none of these physiological changes is associated with thyroid dysfunction, although the equilibria between thyroid hormones and TSH are profoundly altered. Similar changes in control modes are observed in aging (55). In the Baltimore Longitudinal Study of Aging, some participants experienced a parallel rise/fall of TSH and FT4, whereas others showed a rising TSH with declining FT4 concentrations (55). Interestingly, the two patterns carried different mortality risks (55). Underlying mechanisms are complex and confounded by other pathologies, but pituitary

responsiveness is clearly age related, as is deiodinase activity (56–58). Generally, higher TSH ranges are deemed acceptable in the elderly patient (57, 59, 60). More dramatic perturbations occur in severe non-thyroidal illness (NTI) including psychiatric disease (**Figure 1C**) where the allostatic stress response operates to alter both the setpoint and peripheral transfer parameters of the control loop, as reviewed elsewhere (36).

These lines of evidence suggest that equilibria and correlations between TSH, FT4, and FT3 are by no means invariant; rather being situationally adjusted in response to minor disturbances, and completely deranged in severe pathology (**Figure 1B**).

The pituitary–thyroid feedback loop must be revisited in the light of these findings (27). The strong log-linear correlation between TSH and FT4, observed in primary hypothyroidism, disintegrates toward the euthyroid range (61–65). The statistical correlation between TSH and FT4 is invalidated by clustering of

genetically determined TSH–FT4 pairs (**Figure 1B**), and influences other than TSH shape the interrelations and equilibria (**Figure 1C**) (37, 65). This results in a high-individuality index of TSH, which gravely limits the use of population statistics in determining the euthyroid range (66, 67). Hypothalamic–pituitary–thyroid control is more complex and frequently denies the diagnostic simplification of a fixed log-linear TSH–FT4 gradient (**Figures 1A–C**) (27, 68). Studies in levothyroxine (LT4)-treated patients with thyroid carcinoma favor cascade-type control involving FT4, FT3 and their interaction over simple proportional control (38). Setpoint simulations corroborated these clinical results (37, 38). Together these findings question, the current diagnostic use of the TSH response as a reliable mirror of thyroid status. They demand a conceptional evolution of thyroid regulation to underpin a more differentiated clinical use.

APPROPRIATENESS VERSUS NORMALITY

The appropriateness of a TSH level is a different concept from range consideration. In secondary hypothyroidism or hypopituitarism, TSH measurement may be frequently inappropriate, residing within its reference range, yet abnormally low relative to the low-FT4 level. Deranged setpoints together with normal or elevated FT4 concentrations have been well recognized in TSH or thyroid hormone resistance syndromes and TSH producing pituitary tumors. Similarly, low-FT3 and/or low-FT4 serum concentrations in the NTI syndrome are accompanied by variable TSH values within or outside the reference range (4, 5, 36, 69–72). The isolated interpretation of TSH is not diagnostically useful in these conditions. While these limitations are well known, the dominance of TSH in the diagnosis of euthyroidism and as a treatment target for primary hypothyroidism also warrants closer scrutiny.

The high-individuality index of TSH and its correlative variation with thyroid hormones cause major statistical issues, because the basic concept of statistical hypothesis testing demands that the sample is randomly drawn from a population and thus representative of the population (73). This tenet is, however, violated where a measured TSH value is not an expression of normality surrounded by some margin of error or variation within a given population, rather a heterogeneous group of individuals sharing the same TSH value with different physiological meaning. For some individuals, the same TSH value may indicate a perfectly normal situation, for others subtle thyroid failure with declining FT4 concentrations and negative correlation between the two hormones, and for others a control shift to a positive TSH–FT4 correlation induced by non-thyroidal influences. A known response heterogeneity, however, precludes the use of statistical regression models based on normality assumption, requiring multilevel, hierarchical, or latent class models instead (74). The heterogeneity bias is known as Simpson's amalgamation paradox (75, 76). Misleading and conflicting results may therefore be expected when mixing different underlying physiologies without proper stratification. Some authors reported a protective effect of TSH in the elderly, others an increased mortality risk of higher TSH within the normal range, and others no association of death with TSH, but with higher FT4 (21, 77–81).

A dissociation between TSH and FT4 is also apparent in atrial fibrillation in euthyroid individuals where the risk increases with higher FT4 concentrations, but not lower TSH levels (82). We face a similar paradox in RCTs comparing T3–T4 combinations with T4 monotherapy, where patients invariably expressed their preference for the combination, but statistical analysis finds no evidence of superiority (83, 84).

We conclude that a TSH measurement representing ambiguous and overlapping categories between thyroid health and disease is by itself unreliable as a diagnostic tool. Statistical averaging or arbitrary cut-offs such as tertiles or quartiles should not be based on false assumptions of normality without further clinically meaningful stratification.

Another situation that differs from any naturally occurring condition is LT4 monotherapy for primary hypothyroidism. The homeostatic equilibria between TSH, FT4, and FT3 adequate for the previously healthy state no longer apply equally to the treated state, where dissociations between FT4 and FT3 and TSH and FT3 are apparent (**Figures 1D,E**) (31, 33, 65, 85–87). The T3/T4 conversion rate is reduced in LT4-treated athyreotic patients, compared with their rate prior to surgery (38, 86). FT3 is displaced from TSH in these patients, being relatively lower at the same TSH level (33, 85). While the consequences of the altered ratios are widely unknown and require further study (88), implications for the interpretation of TSH measurements can be readily derived.

Thyroid-stimulating hormone concentrations in normal health cannot be a therapeutic target for establishing LT4 dose adequacy (31, 89, 90). The treatment situation has to be re-evaluated on the basis of the shifted equilibria rather than pre-existing range considerations.

Can't we just rely on bringing TSH within an acceptable population range and assume peripheral autoregulation at the tissue level should take care of the adequate tissue supply with T3? There are two major issues with this popular belief in the ability of the patient's own pituitary gland—except for pituitary deficiency—to be the best judge of dose adequacy. First, this leaves patients frequently dissatisfied, because their quality of life is not generally restored with LT4 treatment to the same level seen in healthy persons despite their TSH concentrations being within the reference range (29). Second, the TSH for a patient on LT4 is not what it is for an untreated patient (65). The clinical and biochemical treatment response to LT4 turns out to be diverse and is influenced by many treatment-related or unrelated factors (**Figures 1D,E**) (38, 89). As a consequence of low-conversion efficiency, at least in some patients, the equilibrium for TSH may be shifted below the reference range of the healthy population (38, 86, 89). This poses a dilemma to clinicians.

TOWARD AN OPTIMIZED TREATMENT STRATEGY

Given the fundamental changes in thyroid control related to LT4 medication, we can no longer dismiss patient complaints when discrepancies arise between clinically hypothyroid versus

biochemically euthyroid states (23–26). A recent retrospective study in patients with thyroid carcinoma followed long term found that displaced equilibria and resulting lower FT3 concentrations were associated with a lack of symptom relief, independently of known confounders such as gender, age, body weight, and weight-adjusted LT4 dose (38). This study and others contradict the assumption that patients may invariably gain satisfaction from LT4 treatment when TSH levels are kept within or even below reference range (29, 38, 90). Unfortunately, tissue T3 concentrations or T3 receptor saturation cannot be readily determined in humans. This was, however, done in rodents where various tissues remained in the hypothyroid state on LT4 monotherapy despite normal serum TSH levels, and only T3/T4 combination could restore euthyroidism in tissues (91, 92). These experiments uncovered limiting biochemical pathways that affect local sensitivity to T4 such as ubiquitination of hypothalamic type 2 deiodinase (92).

Implications emerging from advances in the understanding of the diverse facets of pituitary control (Figures 1A–E), clinical studies, mathematical simulations, and experimental treatments suggest replacing the current TSH paradigm with a more inclusive interpretation. This should take into account clinical signs and symptoms, all three thyroid parameters, and their relationships. The appropriateness of the respective levels relative to each other, to the previous healthy state and to a specific condition becomes more important than a blanket categorization according to placements within or outside any set range (Table 1).

If required for symptom relief, considering wide variations in individual responses, clinicians may find it acceptable to suppress the TSH close to or slightly below its reference range while avoiding overt clinical or biochemical hyperthyroidism. In fact, in a recent study, patients after thyroidectomy with mildly suppressed TSH levels were closest to euthyroid, based on surrogate markers for end organ response, those with normal TSH mildly hypothyroid and those with strongly suppressed

levels mildly hyperthyroid (90). T3/T4 combination therapy may be preferable to patients with persistent symptoms or a failure to sufficiently raise their FT3 concentration despite LT4 dose escalation and TSH suppression (93).

This practice should not be discouraged by incorrect statistical analyses of epidemiological studies. Many studies reported increased risks associated with suppressed TSH such as atrial fibrillation and osteoporosis but failed to properly classify the hormone status of patients into euthyroid versus hyperthyroid, and frequently did not even distinguish between treatment-induced TSH suppression and endogenous hyperthyroidism (94). Importantly, thyroid hormones, while suppressing pituitary TSH, have been reported to upregulate the locally produced osteoprotective TSH β v variant (95). Statistical associations with TSH cannot establish causality, as the opposing effects of low-TSH and low-FT3/TSH β v frequently occur together in LT4-treated patients.

However, it is equally appropriate to stress a caveat that not every patient on LT4 may require or tolerate a suppressed TSH. Unfortunately, conventional range considerations for TSH do not apply to the LT4-treated patient. There is no easy fix, but a paradigm shift could be a first step toward a solution. Until more personalized methods such as setpoint reconstruction have been evaluated (37), treatment adequacy must be judged on an individual basis by a combination of clinical and biochemical outcomes. The frequent overlapping and unspecific nature of hypothyroid symptoms presents yet another challenge (96–99). Unfortunately, reliable and readily accessible markers of the tissue effects are lacking.

However, the hypothyroid patient should not opt for under-treatment and forego symptom relief out of an exaggerated fear of over-treatment. On the other hand, long-term risks of LT4 treatment should also be carefully evaluated. Assessing scientific studies is a difficult task because statistical masking, confounding, and response heterogeneity can all be expected in a statistical

TABLE 1 | Differences between the thyroid-stimulating hormone (TSH) paradigm and the newly proposed paradigm.

TSH paradigm	New relational paradigm
Normality-based statistics	Homeostatic equilibria
Univariate normal distribution	Multivariate distributions
Population-based range	Setpoint, joined TSH–FT4 pairs
Low degree of individuality	High-individuality index
TSH is reflective of thyroid hormone status	TSH is interlocked with FT4 and FT3
The reference range is fixed across individuals and conditions	The setpoint is genetically determined and adjustable to various conditions
The parameters are treated as singularities, even when interpreted in combination	The parameters are interpreted in relation to each other
Interpreting ranges	Reconstructing setpoints
Levels are interpreted as within the reference range or outside its limits	Levels are interpreted as relatively appropriate or inappropriate
A TSH within its reference range in a healthy population indicates euthyroidism	The population-based TSH reference range is too wide to reliably define euthyroidism in a person
A high TSH indicates overt or subclinical hypothyroidism with rare exceptions	A high TSH originates from diverse physiologies
The setting of reference ranges and their interpretation is a simple process	The derivation of conjoined homeostatic equilibria is an intricate process
Subclinical thyroid disease entities are solely based on laboratory measurements and do not correspond to treatable clinical entities	The clinical change or challenge is considered primary mounting a defensive reaction that may alter the setpoint or transfer function
TSH is frequently interpreted without sufficient consideration of the clinical situation	The interpretation of TSH is tied to the clinical presentation
TSH reference range is universally suitable to judge treatment success	TSH level is inadequate as a measure of treatment success and LT4 dose adequacy
The suitable TSH range remains unchanged in LT4-treated patients	The suitable TSH range is shifted in LT4-treated patients
Exclusive role of TSH in guiding treatment targets	Supportive role of FT3 in guiding treatment targets

parameter with a high-individuality index (67, 100, 101). This includes RCTs, regarded as the highest class of empirical evidence, which are not immune from violations of the underlying statistical assumptions.

Simplified concepts such as the negative thyroid pituitary feedback control contributed a fundamental understanding of endocrine principles, but were subsequently not refined for dealing with more complex facets of the various thyroid disorders and the clinical requirements of the diagnostic process. The pituitary TSH response is too diverse to be viewed as a sensitive mirror image of thyroid function. The interlocking elements of the control system are highly individual, dynamic, and adaptive. The assumed negative TSH–FT4 association that underpins the diagnostic use of TSH becomes frequently uncorrelated or even inverted, involving various influences, and mechanisms such as statistically multivariate clustering of TSH–FT4 setpoints, non-proportional cascade-type control, control mode shifts from negative feedback to positive tracking,

and prevalent extra-pituitary–thyroid modulators of the relationship. Discrepancies arise between individually appropriate TSH levels and population-based reference ranges, laboratory-based disease definitions and treatment requirements, feedback adjustments and thyroid failure, and non-shared equilibria between thyroid health and LT4 treatment (**Table 1**). These have to be conceptually reconciled to meet the needs of patients and clinical practitioners. TSH should be viewed as a controlling element and interpreted within its physiological role as a more narrowly defined and conditionally adaptive setpoint (**Figure 1**). Novel testable concepts are emerging and await clinical study.

AUTHOR CONTRIBUTIONS

RH and JM drafted the main part of the manuscript. RL and JD edited the text and contributed additional ideas, material, and text passages. JD also contributed to figures. All authors read and approved the final version.

REFERENCES

- Hoermann R, Midgley JEM, Larisch R, Dietrich JW. Relational stability in the expression of normality, variation, and control of thyroid function. *Front Endocrinol* (2016) 7:57–8. doi:10.3389/fendo.2016.00142
- Braverman LE, Utiger RD. Introduction to thyrotoxicosis. In: Braverman LE, Utiger RD, editors. *Werner and Ingbar's The Thyroid*. Philadelphia: J.B. Lippincott Company (1995). p. 645–7.
- Chaker L, Bianco AC, Jonklaas J, Peeters RP. Hypothyroidism. *Lancet* (2017) 390:1550–62. doi:10.1016/S0140-6736(17)30703-1
- Beck-Peccoz P, Rodari G, Giavoli C, Lania A. Central hypothyroidism—a neglected thyroid disorder. *Nat Rev Endocrinol* (2017) 13:588–98. doi:10.1038/nrendo.2017.47
- Grasberger H, Refetoff S. Resistance to thyrotropin. *Best Pract Res Clin Endocrinol Metab* (2017) 31:183–94. doi:10.1016/j.beem.2017.03.004
- Baloch Z, Carayon P, Conte-Devolx B, Demers LM, Feldt-Rasmussen U, Henry J-F, et al. Laboratory medicine practice guidelines. Laboratory support for the diagnosis and monitoring of thyroid disease. *Thyroid* (2003) 13:3–126. doi:10.1089/105072503321086962
- Spencer CA. Thyroid function tests: assay of thyroid hormones and related substances. *Thyroid Disease Manager*. (2017). Available from: <http://www.thyroidmanager.org/chapter/assay-of-thyroid-hormones-and-related-substances3/>
- Cooper DS. Clinical practice. Subclinical hypothyroidism. *N Engl J Med* (2001) 345:260–5. doi:10.1056/NEJM200107263450406
- Redford C, Vaidya B. Subclinical hypothyroidism: should we treat? *Post Reprod Health* (2017) 23:55–62. doi:10.1177/2053369117705058
- Larsen PR. Thyroid-pituitary interaction: feedback regulation of thyrotropin secretion by thyroid hormones. *N Engl J Med* (1982) 306:23–32. doi:10.1056/NEJM198201073060107
- Thienpont LM, Van Uytenghe K, Beastall G, Faix JD, Ieri T, Miller WG, et al. Report of the IFCC Working Group for standardization of thyroid function tests; part 1: thyroid-stimulating hormone. *Clin Chem* (2010) 56:902–11. doi:10.1373/clinchem.2009.140178
- Caldwell G, Kellett HA, Gow SM, Beckett GJ, Sweeting VM, Seth J, et al. A new strategy for thyroid function testing. *Lancet* (1985) 1:1117–9. doi:10.1016/S0140-6736(85)92429-8
- Sheehan MT. Biochemical testing of the thyroid: TSH is the best and, often-times, only test needed—a review for primary care. *Clin Med Res* (2016) 14:83–92. doi:10.3121/cmr.2016.1309
- Pearce SHS, Brabant G, Duntas LH, Monzani F, Peeters RP, Razvi S, et al. 2013 ETA guideline: management of subclinical hypothyroidism. *Eur Thyroid J* (2013) 2:215–28. doi:10.1159/000356507
- Jonklaas J, Bianco AC, Bauer AJ, Burman KD, Cappola AR, Celi FS, et al. Guidelines for the treatment of hypothyroidism: prepared by the American Thyroid Association task force on thyroid hormone replacement. *Thyroid* (2014) 24:1670–751. doi:10.1089/thy.2014.0028
- Ross DS, Burch HB, Cooper DS, Greenlee MC, Laurberg P, Maia AL, et al. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. *Thyroid* (2016) 26:1343–421. doi:10.1089/thy.2016.0229
- Alexander EK, Pearce EN, Brent GA, Brown RS, Chen H, Dosiou C, et al. 2017 guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and the postpartum. *Thyroid* (2017) 27:315–89. doi:10.1089/thy.2016.0457
- Rodondi N, Elzen den WPJ, Bauer DC, Cappola AR, Razvi S, Walsh JP, et al. Subclinical hypothyroidism and the risk of coronary heart disease and mortality. *JAMA* (2010) 304:1365–74. doi:10.1001/jama.2010.1361
- Rieben C, Segna D, da Costa BR, Collet T-H, Chaker L, Aubert CE, et al. Subclinical thyroid dysfunction and the risk of cognitive decline: a meta-analysis of prospective cohort studies. *J Clin Endocrinol Metab* (2016) 101:4945–54. doi:10.1210/jc.2016-2129
- Chaker L, Korevaar TIM, Rizopoulos D, Collet TH, Völzke H, Hofman A, et al. Defining optimal health range for thyroid function based on the risk of cardiovascular disease. *J Clin Endocrinol Metab* (2017) 102:2853–61. doi:10.1210/jc.2017-00410
- Inoue K, Tsujimoto T, Saito J, Sugiyama T. Association between serum thyrotropin levels and mortality among euthyroid adults in the United States. *Thyroid* (2016) 26:1457–65. doi:10.1089/thy.2016.0156
- Zulewski H, Müller B, Exer P, Miserez AR, Staub JJ. Estimation of tissue hypothyroidism by a new clinical score: evaluation of patients with various grades of hypothyroidism and controls. *J Clin Endocrinol Metab* (1997) 82:771–6. doi:10.1210/jc.82.3.771
- Saravanan P, Chau W-F, Roberts N, Vedhara K, Greenwood R, Dayan CM. Psychological well-being in patients on “adequate” doses of l-thyroxine: results of a large, controlled community-based questionnaire study. *Clin Endocrinol (Oxf)* (2002) 57:577–85. doi:10.1046/j.1365-2265.2002.01654.x
- Wekking EM, Appelhof BC, Fliers E, Schene AH, Huysen J, Tijssen JGP, et al. Cognitive functioning and well-being in euthyroid patients on thyroxine replacement therapy for primary hypothyroidism. *Eur J Endocrinol* (2005) 153:747–53. doi:10.1530/eje.1.02025
- Skinner GRB, Holmes D, Ahmad A, Davies JA, Benitez J. Clinical response to thyroxine sodium in clinically hypothyroid but biochemically euthyroid patients. *J Nutr Environ Med* (2009) 10:115–24. doi:10.1080/135908400500043530
- Panicker V, Evans J, Bjoro T, Asvold BO, Dayan CM, Bjerkeset O. A paradoxical difference in relationship between anxiety, depression and thyroid function in subjects on and not on T4: findings from the HUNT study. *Clin Endocrinol (Oxf)* (2009) 71:574–80. doi:10.1111/j.1365-2265.2008.03521.x

27. Hoermann R, Midgley JEM, Larisch R, Dietrich JW. Homeostatic control of the thyroid–pituitary axis: perspectives for diagnosis and treatment. *Front Endocrinol* (2015) 6:1–17. doi:10.3389/fendo.2015.00177
28. McAninch EA, Bianco AC. New insights into the variable effectiveness of levothyroxine monotherapy for hypothyroidism. *Lancet Diabetes Endocrinol* (2015) 3:756–8. doi:10.1016/S2213-8587(15)00325-3
29. Winther KH, Cramon P, Watt T, Bjorner JB, Ekholm O, Feldt-Rasmussen U, et al. Disease-specific as well as generic quality of life is widely impacted in autoimmune hypothyroidism and improves during the first six months of levothyroxine therapy. *PLoS One* (2016) 11:e0156925. doi:10.1371/journal.pone.0156925
30. Ishii H, Inada M, Tanaka K, Mashio Y, Naito K, Nishikawa M, et al. Induction of outer and inner ring monodeiodinases in human thyroid gland by thyrotropin. *J Clin Endocrinol Metab* (1983) 57:500–5. doi:10.1210/jcem-57-3-500
31. Hoermann R, Midgley JEM, Larisch R, Dietrich JW. Integration of peripheral and glandular regulation of triiodothyronine production by thyrotropin in untreated and thyroxine-treated subjects. *Horm Metab Res* (2015) 47:674–80. doi:10.1055/s-0034-1398616
32. Citterio CE, Veluswamy B, Morgan SJ, Galton VA, Banga JP, Atkins S, et al. De novo triiodothyronine formation from thyrocytes activated by thyroid-stimulating hormone. *J Biol Chem* (2017) 292:15434–44. doi:10.1074/jbc.M117.784447
33. Hoermann R, Midgley JEM, Larisch R, Dietrich JW. Is pituitary TSH an adequate measure of thyroid hormone-controlled homeostasis during thyroxine treatment? *Eur J Endocrinol* (2013) 168:271–80. doi:10.1530/EJE-12-0819
34. Hoermann R, Midgley JEM, Larisch R, Dietrich JW. Relational stability of thyroid hormones in euthyroid subjects and patients with autoimmune thyroid disease. *Eur Thyroid J* (2016) 5:171–9. doi:10.1159/000447967
35. Russell W, Harrison RF, Smith N, Darzy K, Shalet S, Weetman AP, et al. Free triiodothyronine has a distinct circadian rhythm that is delayed but parallels thyrotropin levels. *J Clin Endocrinol Metab* (2008) 93:2300–6. doi:10.1210/jc.2007-2674
36. Chatzitomaris A, Hoermann R, Midgley JE, Hering S, Urban A, Dietrich B, et al. Thyroid allostasis-adaptive responses of thyrotropic feedback control to conditions of strain, stress, and developmental programming. *Front Endocrinol* (2017) 8:163. doi:10.3389/fendo.2017.00163
37. Hoermann R, Midgley JEM, Larisch R, Dietrich JW. Advances in applied homeostatic modelling of the relationship between thyrotropin and free thyroxine. *PLoS One* (2017) 12(11):e0187232. doi:10.1371/journal.pone.0187232
38. Hoermann R, Midgley JEM, Dietrich JW, Larisch R. Dual control of pituitary thyroid stimulating hormone secretion by thyroxine and triiodothyronine in athyreotic patients. *Ther Adv Endocrinol Metab* (2017) 8:83–95. doi:10.1177/2042018817716401
39. Reinehr T. Thyroid function in the nutritionally obese child and adolescent. *Curr Opin Pediatr* (2011) 23:415–20. doi:10.1097/MOP.0b013e328344c393
40. Hoermann R, Cheung AS, Milne M. Hypothalamic-pituitary-thyroid axis setpoint alterations are associated with body composition in androgen deprived men. *J Endocr Soc* (2017) 1:874–85. doi:10.1210/js.2017-00057
41. Rodríguez EM, Blázquez JL, Pastor FE, Peláez B, Peña P, Peruzzo B, et al. Hypothalamic tanycytes: a key component of brain–endocrine interaction. *Int Rev Cytol* (2005) 247:89–164. doi:10.1016/S0074-7696(05)47003-5
42. Fekete C, Lechan RM. Negative feedback regulation of hypophysiotropic thyrotropin-releasing hormone (TRH) synthesizing neurons: role of neuronal afferents and type 2 deiodinase. *Front Neuroendocrinol* (2007) 28:97–114. doi:10.1016/j.yfrne.2007.04.002
43. Visser WE, Friesema ECH, Visser TJ. Minireview: thyroid hormone transporters: the knowns and the unknowns. *Mol Endocrinol* (2011) 25:1–14. doi:10.1210/me.2010-0095
44. Kalló I, Mohácsik P, Vida B, Zeöld A, Bardóczy Z, Zavacki AM, et al. A novel pathway regulates thyroid hormone availability in rat and human hypothalamic neurosecretory neurons. *PLoS One* (2012) 7:e37860. doi:10.1371/journal.pone.0037860
45. Fekete C, Lechan RM. Central regulation of hypothalamic-pituitary-thyroid axis under physiological and pathophysiological conditions. *Endocr Rev* (2014) 35:159–94. doi:10.1210/er.2013-1087
46. Gereben B, McAninch EA, Ribeiro MO, Bianco AC. Scope and limitations of iodothyronine deiodinases in hypothyroidism. *Nat Rev Endocrinol* (2015) 11:642–52. doi:10.1038/nrendo.2015.155
47. Herwig A, Campbell G, Mayer C-D, Boelen A, Anderson RA, Ross AW, et al. A thyroid hormone challenge in hypothyroid rats identifies T3 regulated genes in the hypothalamus and in models with altered energy balance and glucose homeostasis. *Thyroid* (2014) 24:1575–93. doi:10.1089/thy.2014.0169
48. Joseph-Bravo P, Jaimes-Hoy L, Charli J-L. Regulation of TRH neurons and energy homeostasis-related signals under stress. *J Endocrinol* (2015) 224:R139–59. doi:10.1530/JOE-14-0593
49. Menendez C, Baldelli R, Camiña JP, Escudero B, Peino R, Dieguez C, et al. TSH stimulates leptin secretion by a direct effect on adipocytes. *J Endocrinol* (2003) 176:7–12. doi:10.1677/joe.0.1760007
50. Reinehr T, de Sousa G, Andler W. Hyperthyrotropinemia in obese children is reversible after weight loss and is not related to lipids. *J Clin Endocrinol Metab* (2006) 91:3088–91. doi:10.1210/jc.2006-0095
51. Biondi B. Thyroid and obesity: an intriguing relationship. *J Clin Endocrinol Metab* (2010) 95:3614–7. doi:10.1210/jc.2010-1245
52. Gereben B, Zavacki AM, Ribich S, Kim BW, Huang SA, Simonides WS, et al. Cellular and molecular basis of deiodinase-regulated thyroid hormone signaling. *Endocr Rev* (2008) 29:898–938. doi:10.1210/er.2008-0019
53. Bernal J, Guadaño-Ferraz A, Morte B. Thyroid hormone transporters—functions and clinical implications. *Nat Rev Endocrinol* (2015) 11:406–17. doi:10.1038/nrendo.2015.66
54. Wan W, Farboud B, Privalsky ML. Pituitary resistance to thyroid hormone syndrome is associated with T3 receptor mutants that selectively impair beta2 isoform function. *Mol Endocrinol* (2005) 19:1529–42. doi:10.1210/me.2005-0014
55. Mammen JS, McGready J, Ladenson PW, Simonsick EM. Unstable thyroid function in older adults is caused by alterations in both thyroid and pituitary physiology and associated with increased mortality. *Thyroid* (2017) 27:1370–7. doi:10.1089/thy.2017.0211
56. Carle A, Laurberg P, Pedersen IB, Perrild H, Ovesen L, Rasmussen LB, et al. Age modifies the pituitary TSH response to thyroid failure. *Thyroid* (2007) 17:139–44. doi:10.1089/thy.2006.0191
57. Peeters RP. Thyroid hormones and aging. *Hormones* (2008) 7:28–35. doi:10.14310/horm.2002.1111035
58. Strich D, Karavani G, Edri S, Gillis D. TSH enhancement of FT4 to FT3 conversion is age dependent. *Eur J Endocrinol* (2016) 175:49–54. doi:10.1530/EJE-16-0007
59. Vadiveloo T, Donnan PT, Murphy MJ, Leese GP. Age- and gender-specific TSH reference intervals in people with no obvious thyroid disease in Tayside, Scotland: the thyroid epidemiology, audit, and research study (TEARS). *J Clin Endocrinol Metab* (2013) 98:1147–53. doi:10.1210/jc.2012-3191
60. Ehrenkranz J, Bach PR, Snow GL, Schneider A, Lee JL, Ilstrup S, et al. Circadian and circannual rhythms in thyroid hormones: determining the TSH and free T4 reference intervals based upon time of day, age, and sex. *Thyroid* (2015) 25:954–61. doi:10.1089/thy.2014.0589
61. Hoermann R, Eckl WA, Hoermann C, Larisch R. Complex relationship between free thyroxine and TSH in the regulation of thyroid function. *Eur J Endocrinol* (2010) 162:1123–9. doi:10.1530/EJE-10-0106
62. Clark PMS, Holder RL, Haque SM, Hobbs FDR, Roberts LM, Franklyn JA. The relationship between serum TSH and free T4 in older people. *J Clin Pathol* (2012) 65:463–5. doi:10.1136/jclinpath-2011-200433
63. Midgley JEM, Hoermann R, Larisch R, Dietrich JW. Physiological states and functional relation between thyrotropin and free thyroxine in thyroid health and disease: in vivo and in silico data suggest a hierarchical model. *J Clin Pathol* (2013) 66:335–42. doi:10.1136/jclinpath-2012-201213
64. Hadlow NC, Rothacker KM, Wardrop R, Brown SJ, Lim EM, Walsh JP. The relationship between TSH and free T₄ in a large population is complex and nonlinear and differs by age and sex. *J Clin Endocrinol Metab* (2013) 98:2936–43. doi:10.1210/jc.2012-4223
65. Hoermann R, Midgley JEM, Giacobino A, Eckl WA, Wahl HG, Dietrich JW, et al. Homeostatic equilibria between free thyroid hormones and pituitary thyrotropin are modulated by various influences including age, body mass index and treatment. *Clin Endocrinol (Oxf)* (2014) 81:907–15. doi:10.1111/cen.12527
66. Andersen S, Pedersen KM, Bruun NH, Laurberg P. Narrow individual variations in serum T(4) and T(3) in normal subjects: a clue to the understanding

- of subclinical thyroid disease. *J Clin Endocrinol Metab* (2002) 87:1068–72. doi:10.1210/jcem.87.3.8165
67. van de Ven AC, Netea-Maier RT, Medici M, Sweep FCGJ, Ross HA, Hofman A, et al. Underestimation of effect of thyroid function parameters on morbidity and mortality due to intra-individual variation. *J Clin Endocrinol Metab* (2011) 96:E2014–7. doi:10.1210/jc.2011-0680
 68. Brown SJ, Bremner AP, Hadlow NC, Feddema P, Leedman PJ, O'Leary PC, et al. The log TSH-free T4 relationship in a community-based cohort is nonlinear and is influenced by age, smoking and thyroid peroxidase antibody status. *Clin Endocrinol (Oxf)* (2016) 85:789–96. doi:10.1111/cen.13107
 69. Fliers E, Kalsbeek A, Boelen A. Beyond the fixed setpoint of the hypothalamus-pituitary-thyroid axis. *Eur J Endocrinol* (2014) 171:R197–208. doi:10.1530/EJE-14-0285
 70. Boonen E, Van den Berghe G. Endocrine responses to critical illness: novel insights and therapeutic implications. *J Clin Endocrinol Metab* (2014) 99:1569–82. doi:10.1210/jc.2013-4115
 71. Van den Berghe G. Non-thyroidal illness in the ICU: a syndrome with different faces. *Thyroid* (2014) 24:1456–65. doi:10.1089/thy.2014.0201
 72. Goemann IM, Romitti M, Meyer ELS, Wajner SM, Maia AL. Role of thyroid hormones in the neoplastic process: an overview. *Endocr Relat Cancer* (2017) 24:R367–85. doi:10.1530/ERC-17-0192
 73. Yates DS, Moore DS, Starnes DS. *The Practice of Statistics*. 3rd ed. New York: WH Freeman and Company (2008).
 74. Muthén BO. Latent variable modeling in heterogeneous populations. *Psychometrika* (1989) 54:557–85. doi:10.1007/BF02296397
 75. Simpson EH. The interpretation of interaction in contingency tables. *J R Stat Soc* (1951) 13:238–41.
 76. Wagner CH. Simpson's paradox in real life. *Am Stat* (1982) 36:46. doi:10.2307/2684093
 77. Gussekloo J, van Exel E, de Craen AJM, Meinders AE, Frölich M, Westendorp RGJ. Thyroid status, disability and cognitive function, and survival in old age. *JAMA* (2004) 292:2591–9. doi:10.1001/jama.292.21.2591
 78. van den Beld AW, Visser TJ, Feelders RA, Grobbee DE, Lamberts SWJ. Thyroid hormone concentrations, disease, physical function, and mortality in elderly men. *J Clin Endocrinol Metab* (2005) 90:6403–9. doi:10.1210/jc.2005-0872
 79. Waring AC, Arnold AM, Newman AB, Bůzková P, Hirsch C, Cappola AR. Longitudinal changes in thyroid function in the oldest old and survival: the cardiovascular health study all-stars study. *J Clin Endocrinol Metab* (2012) 97:3944–50. doi:10.1210/jc.2012-2481
 80. Yeap BB, Alfonso H, Hankey GJ, Flicker L, Golledge J, Norman PE, et al. Higher free thyroxine levels are associated with all-cause mortality in euthyroid older men: the health in men study. *Eur J Endocrinol* (2013) 169:401–8. doi:10.1530/EJE-13-0306
 81. Selmer C, Olesen JB, Hansen ML, Kappelgaard von LM, Madsen JC, Hansen PR, et al. Subclinical and overt thyroid dysfunction and risk of all-cause mortality and cardiovascular events: a large population study. *J Clin Endocrinol Metab* (2014) 99:2372–82. doi:10.1210/jc.2013-4184
 82. Baumgartner C, da Costa BR, Collet T-H, Feller M, Floriani C, Bauer DC, et al. Thyroid function within the normal range, subclinical hypothyroidism and the risk of atrial fibrillation. *Circulation* (2017) 136:2100–16. doi:10.1161/CIRCULATIONAHA.117.028757
 83. Grozinsky-Glasberg S, Fraser A, Nahshoni E, Weizman A, Leibovici L. Thyroxine-triiodothyronine combination therapy versus thyroxine monotherapy for clinical hypothyroidism: meta-analysis of randomized controlled trials. *J Clin Endocrinol Metab* (2006) 91:2592–9. doi:10.1210/jc.2006-0448
 84. Wiersinga WM. Therapy of endocrine disease: T4+T3 combination therapy: is there a true effect? *Eur J Endocrinol* (2017) 177:R287–96. doi:10.1530/EJE-17-0645
 85. Gullo D, Latina A, Frasca F, Le Moli R, Pellegriti G, Vigneri R. Levothyroxine monotherapy cannot guarantee euthyroidism in all athyreotic patients. *PLoS One* (2011) 6:e22552. doi:10.1371/journal.pone.0022552
 86. Ito M, Miyauchi A, Morita S, Kudo T, Nishihara E, Kihara M, et al. TSH-suppressive doses of levothyroxine are required to achieve preoperative native serum triiodothyronine levels in patients who have undergone total thyroidectomy. *Eur J Endocrinol* (2012) 167:373–8. doi:10.1530/EJE-11-1029
 87. Ito M, Miyauchi A, Kang S, Hisakado M, Yoshioka W, Ide A, et al. Effect of the presence of remnant thyroid tissue on the serum thyroid hormone balance in thyroidectomized patients. *Eur J Endocrinol* (2015) 173:333–40. doi:10.1530/EJE-15-0138
 88. Peterson SJ, McAninch EA, Bianco AC. Is a normal TSH synonymous with “euthyroidism” in levothyroxine monotherapy? *J Clin Endocrinol Metab* (2016) 101:4964–73. doi:10.1210/jc.2016-2660
 89. Midgley JEM, Larisch R, Dietrich JW, Hoermann R. Variation in the biochemical response to L-thyroxine therapy and relationship with peripheral thyroid hormone conversion. *Endocr Connect* (2015) 4:196–205. doi:10.1530/EC-15-0056
 90. Ito M, Miyauchi A, Hisakado M, Yoshioka W, Ide A, Kudo T, et al. Biochemical markers reflecting thyroid function in athyreotic patients on levothyroxine monotherapy. *Thyroid* (2017) 27:484–90. doi:10.1089/thy.2016.0426
 91. Escobar-Morreale HF, del Rey FE, Obregón MJ, de Escobar GM. Only the combined treatment with thyroxine and triiodothyronine ensures euthyroidism in all tissues of the thyroidectomized rat. *Endocrinology* (1996) 137:2490–502. doi:10.1210/endo.137.6.8641203
 92. Werneck de Castro JP, Fonseca TL, Ueta CB, McAninch EA, Abdalla SM, Wittmann G, et al. Differences in hypothalamic type 2 deiodinase ubiquitination explain localized sensitivity to thyroxine. *J Clin Invest* (2015) 125:769–81. doi:10.1172/JCI77588
 93. Wiersinga WM, Duntas L, Fadeyev V, Nygaard B, Vanderpump MP. 2012 ETA guidelines: the use of L-T4 + L-T3 in the treatment of hypothyroidism. *Eur Thyroid J* (2012) 1:55–71. doi:10.1159/000339444
 94. Biondi B, Wartofsky L. Treatment with thyroid hormone. *Endocr Rev* (2014) 35:433–512. doi:10.1210/er.2013-1083
 95. Baliram R, Latif R, Zaidi M, Davies TF. Expanding the role of thyroid-stimulating hormone in skeletal physiology. *Front Endocrinol* (2017) 8:758–9. doi:10.3389/fendo.2017.00252
 96. Ott J, Promberger R, Kober F, Neuhold N, Tea M, Huber JC, et al. Hashimoto's thyroiditis affects symptom load and quality of life unrelated to hypothyroidism: a prospective case-control study in women undergoing thyroidectomy for benign goiter. *Thyroid* (2011) 21:161–7. doi:10.1089/thy.2010.0191
 97. Kelderman-Bolk N, Visser TJ, Tijssen JP, Berghout A. Quality of life in patients with primary hypothyroidism related to BMI. *Eur J Endocrinol* (2015) 173:507–15. doi:10.1530/EJE-15-0395
 98. Applewhite MK, James BC, Kaplan SP, Angelos P, Kaplan EL, Grogan RH, et al. Quality of life in thyroid cancer is similar to that of other cancers with worse survival. *World J Surg* (2016) 40:551–61. doi:10.1007/s00268-015-3300-5
 99. Hedman C, Djärv T, Strang P, Lundgren CI. Effect of thyroid-related symptoms on long-term quality of life in patients with differentiated thyroid carcinoma: a population-based study in Sweden. *Thyroid* (2017) 27:1034–42. doi:10.1089/thy.2016.0604
 100. Andersen S, Bruun NH, Pedersen KM, Laurberg P. Biologic variation is important for interpretation of thyroid function tests. *Thyroid* (2003) 13:1069–78. doi:10.1089/105072503770867237
 101. Hoermann R, Midgley JEM. TSH measurement and its implications for personalised clinical decision-making. *J Thyroid Res* (2012) 2012:1–9. doi:10.1089/thy.2008.0155
- Conflict of Interest Statement:** JD received funding and personal fees by Sanofi-Henning, Hexal AG, Bristol-Myers, Squibb, and Pfizer, and is co-owner of the intellectual property rights for the patent “System and Method for Deriving Parameters for Homeostatic Feedback Control of an Individual” (Singapore Institute for Clinical Sciences, Biomedical Sciences Institutes, Application Number 201208940-5, WIPO number WO/2014/088516). All other authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.
- Copyright © 2017 Hoermann, Midgley, Larisch and Dietrich. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.